Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer
•Ultra-hypofractionated radiation for early breast tumors makes treatment more convenient by reducing overall treatment time.•Ultra-hypofractionated simultaneous integrated boost associates low rates of radiation-related acute skin toxicity.•Using a simultaneous boost seems feasible and can improve...
Gespeichert in:
Veröffentlicht in: | Clinical and translational radiation oncology 2023-07, Vol.41, p.100651-100651, Article 100651 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Ultra-hypofractionated radiation for early breast tumors makes treatment more convenient by reducing overall treatment time.•Ultra-hypofractionated simultaneous integrated boost associates low rates of radiation-related acute skin toxicity.•Using a simultaneous boost seems feasible and can improve the benefits of ultra-hypofractionation.
Whole-breast irradiation (WBI) after breast conserving surgery (BCS) is indicated to improve loco-regional control and survival. Former studies showed that addition of tumor bed boost in all age groups significantly improved local control although no apparent impact on overall survival but with an increased risk of worse cosmetic outcome. Even though shortened regimens in 3 weeks are considered the standard, recent studies have shown the non-inferiority of a treatment regimen of 5 fractions in one-week in both locoregional control and toxicity profile, although simultaneous integrated boost (SIB) in this setting has been scarcely studied.
From March-2020 to March-2022, 383 patients with early breast cancer diagnosis and a median age of 56 years-old (range 30–99)were included in a prospective registry of ultra-hypofractionated WBI up to a total dose of 26 Gy in 5.2 Gy/fractionwith a SIB of 29 Gy in 5.8 Gy/fraction in 272 patients (71%), 30–31 Gy in 6–6.2 Gy/fraction in 111 patients (29%) with close/focally affected margins. Radiation treatment was delivered by conformal 3-D technique in 366 patients (95%), VMAT in 16patients (4%) and conformal 3-D with deep inspiration breath hold (DIBH) in 4patients (1%). Ninety-three per cent of patients received endocrine therapy and 43% systemic or targeted chemotherapy. Development of acute skin complications was retrospectively reviewed.
With a median follow-up of 18 months (range 7–31), all patients are alive without evidence of local, regional or distant relapse. Acute tolerance was acceptable, with null o mild toxicity: 182 (48%) and 15 (4%) patients developed skin toxicity grade 1 and 2 respectively; 9 (2%) and 2 (0.5%) patients breast edema grade 1and 2 respectively. No other acute toxicities were observed. We also evaluated development of early delayed complications and observed grade 1 breast edema in 6 patients (2%); grade 1 hyperpigmentation in 20 patients (5%); and grade 1 and 2 breast induration underneath boost region in 10(3%) and 2 patients (0.5%) respectively. We found a statistically significant correlation between the median PTVWBI and presence of skin toxicity (p = |
---|---|
ISSN: | 2405-6308 2405-6308 |
DOI: | 10.1016/j.ctro.2023.100651 |